AstraZeneca PLC Notice of AGM
22 Março 2023 - 08:00AM
UK Regulatory (RNS & others)
RNS Number : 8684T
22 March 2023
22 March 2023 11:00 GMT
Notice of Annual General Meeting and Board Committee change
AstraZeneca PLC (the Company) announced today the publication of
its Notice of Annual General Meeting 2023 and Shareholders'
Circular (the Notice).
The Company also announced that, in line with the UK Corporate
Governance Code, Michel Demaré will step down as a member of the
Audit Committee at the conclusion of this year's Annual General
Meeting (AGM) following his appointment as Chair of the Board.
The Notice and the proxy form for the AGM have been submitted to
the National Storage Mechanism and will shortly be available for
https://data.fca.org.uk/#/nsm/nationalstoragemechanism . The Notice
is also available on the Company's website at
The Company's Annual Report and Form 20-F Information 2022 (the
Annual Report) was published on 21 February 2023.
The Notice is being despatched to shareholders today.
The meeting place for the AGM will be the Leonardo Royal Hotel
London Tower Bridge, 45 Prescot Street, London, E1 8GP and the AGM
will commence at 2.30 pm (BST) on 27 April 2023.
The business to be conducted at the AGM is summarised below:
1. To receive the Company's Accounts, the Reports of the
Directors and Auditor and the Strategic Report for the year ended
31 December 2022
2. To confirm dividends
3. To reappoint PricewaterhouseCoopers LLP as Auditor
4. To authorise the Directors to agree the remuneration of the Auditor
5. To elect or re-elect Directors
6. To approve the Annual Report on Remuneration for the year ended 31 December 2022
7. To authorise limited political donations
8. To authorise the Directors to allot shares
9. To authorise the Directors to disapply pre-emption rights
10. To authorise the Directors to further disapply pre-emption
rights for acquisitions and specified capital investments
11. To authorise the Company to purchase its own shares
12. To reduce the notice period for general meetings
13. To adopt new Articles of Association of the Company.
Pursuant to Regulation 41 of the Uncertificated Securities
Regulations 2001, only holders of ordinary shares entered in the
register of members of the Company by 6.30pm (BST) on 25 April 2023
(or their duly appointed proxies), or if this meeting is adjourned,
in the register of members by 6.30pm (BST) two days prior to any
adjourned meeting, are entitled to attend or vote at the AGM in
respect of the number of ordinary shares registered in their name
at that time. Changes to the entries in the register of members
after 6.30pm (BST) on 25 April 2023, or if this meeting is
adjourned, in the register of members after 6.30pm (BST) two days
prior to any adjourned meeting, shall be disregarded in determining
the rights of any person to attend or vote at the AGM. The Record
Date applied to the Euroclear Sweden system to determine
entitlement to attend and vote at the AGM is close of business on
18 April 2023.
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led
biopharmaceutical company that focuses on the discovery,
development, and commercialisation of prescription medicines in
Oncology, Rare Diseases, and BioPharmaceuticals, including
Cardiovascular, Renal & Metabolism, and Respiratory &
Immunology. Based in Cambridge, UK, AstraZeneca operates in over
100 countries and its innovative medicines are used by millions of
patients worldwide. Please visit astrazeneca.com and follow the
Company on Twitter @AstraZeneca .
For details on how to contact the Investor Relations Team,
please click here . For Media contacts, click here .
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact firstname.lastname@example.org or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
(END) Dow Jones Newswires
March 22, 2023 07:00 ET (11:00 GMT)
Gráfico Histórico do Ativo
De Abr 2023 até Mai 2023
Gráfico Histórico do Ativo
De Mai 2022 até Mai 2023